Journal Review in Surgical Oncology: Gastrointestinal Stromal Tumors (GISTs)

Join the Behind the Knife Surgical Oncology Team as we discuss “One versus Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial,” the randomized trial guiding duration of imatinib treatment for gastrointestinal stromal tumors (GIST).



Hosts:

- Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center.

- Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist and current HPB fellow at MD Anderson.

- Connor Chick, MD (@connor_chick) is a Surgical Oncology fellow at Ohio State University.

- Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a PGY-6 General Surgery resident at Brooke Army Medical Center.

- Beth (Elizabeth) Carpenter, MD (@elizcarpenter16) is a PGY-5 General Surgery resident at Brooke Army Medical Center.



Learning Objectives:



In this episode, we discuss the article “One versus Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial” published in JAMA in 2012. This study demonstrated that 3 years of imatinib led to improved recurrence-free and overall survival compared to 1 year.  



Links to Paper Referenced in this Episode

https://jamanetwork.com/journals/jama/fullarticle/1105116



 ***Fellowship Application - https://forms.gle/5fbYJ1JXv3ijpgCq9***



Please visit https://app.behindtheknife.org/home to access other high-yield surgical education podcasts, videos and more.



If you liked this episode, check out our recent episodes here https://app.behindtheknife.org/listen